{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Number of patients who experienced post-transplant complication (GVHD) as seen by clinical evidence","groups":[{"description":"Patients receiving Fludarabine, Busulfan, cyclophosphamide and post-transplant cyclophosphamide for a haploidentical donor transplant","id":"OG000","title":"Haploidentical Transplant"}],"paramType":"NUMBER","populationDescription":"17 patients were alive at Day 100 and eligible to be evaluated for grade 3-4 graft versus host disease","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)","type":"PRIMARY","unitOfMeasure":"participants"}